IQVIA Holdings AI Stock Analysis
Want to see IQV full AI Analyst Report?
IQVIA Holdings (IQV) AI Stock Analysis
IQVIA Holdings
(NYSE:IQV)
The score is driven primarily by solid fundamentals (steady growth and strong cash generation) and a very positive earnings update with raised FY2026 guidance and strong bookings momentum. Technicals also support the view with price above key moving averages and positive MACD. The main constraints are leverage (financial risk) and a relatively high P/E multiple, with refinancing activity a modest supportive factor.
IQVIA Holdings Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Revenue growth is broadening beyond the Americas: Europe and APAC are the faster-growing regions (APAC showing the steepest recent pickup), turning IQVIA into a more diversified geographic growth story. Management’s raised guidance, accelerating organic growth and strong R&DS bookings/backlog validate that momentum, but expect limited margin leverage near term—FX headwinds, pass‑through revenue and lower‑margin acquisition mix will likely mute profit expansion even as top‑line trajectory improves.
IQVIA Holdings (IQV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $42.45B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.46M
- Price to Earnings (P/E)
- 31.1
- Beta (1Y)
- 0.80
- Revenue Growth
- 8.88%
- EPS Growth
- 13.11%
- Country
- US
- Employees
- 94,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
IQVIA Holdings Business Overview & Revenue Model
Company Description
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-P...
How the Company Makes Money
IQVIA primarily makes money by selling services and technology solutions to life sciences customers under contracts that span research and development through commercialization. A major revenue stream is its CRO/clinical development business, where I...
IQVIA Holdings Earnings Call Summary
The call was strongly positive. IQVIA reported revenue, adjusted EBITDA, and adjusted EPS above guidance; accelerating organic growth across clinical and commercial solutions; record four-year clinical bookings; improving win rates; strong demand indicators; expanding AI adoption; strong free cash flow; and raised full-year guidance. The principal challenges were the $2.1 billion inactive-trial backlog adjustment, pass-through and foreign-exchange headwinds, difficult fourth-quarter comparisons, leverage, and historical market uncertainty, but management explicitly stated that the backlog adjustment did not affect financial results or guidance and emphasized continued operational momentum.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised full year 2026 guidance, expecting revenue to be between 17.350 billion and $17.5 billion, representing year over year growth of 6.4% to 7.3%, with >1 point constant currency or revenue growth acceleration versus prior year, approximately 200 to 250 basis points of contribution from acquisitions, and approximately 20 basis points of tailwind from foreign exchange; adjusted EBITDA is expected to be between 4.025 billion and $4.055 billion, growing 6.3 to 7% year over year with flat margins year over year at approximately 23.2%; adjusted diluted EPS is expected to be between $12.90 and $13, up 8.2 to 9.1% versus prior year or 8.6% at the midpoint; fourth-quarter run rate assumptions include net interest expense around $210 million, just over $160 million in depreciation and amortization, and a weighted average diluted share count of approximately 169 million shares, with foreign currency rates as of October 26th continuing for the balance.
IQVIA Holdings Financial Statement Overview
Summary
Solid operating profile with steady revenue expansion, durable profitability, and strong free cash flow generation. The key offset is a leveraged balance sheet (elevated debt vs. equity and higher sensitivity to rates/refinancing), which limits the overall financial quality despite strong cash generation.
Income Statement
78PositiveBalance Sheet
56NeutralCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.31B | 16.31B | 15.40B | 14.98B | 14.41B | 13.87B |
| Gross Profit | 4.58B | 5.43B | 5.38B | 5.24B | 5.03B | 4.64B |
| EBITDA | 3.60B | 2.94B | 3.45B | 3.26B | 2.91B | 2.77B |
| Net Income | 1.39B | 1.36B | 1.37B | 1.36B | 1.09B | 966.00M |
Balance Sheet | ||||||
| Total Assets | 30.47B | 29.94B | 26.90B | 26.68B | 25.34B | 24.69B |
| Cash, Cash Equivalents and Short-Term Investments | 2.42B | 2.14B | 1.84B | 1.50B | 1.31B | 1.48B |
| Total Debt | 16.31B | 16.17B | 14.16B | 13.90B | 13.01B | 12.44B |
| Total Liabilities | 23.68B | 23.31B | 20.83B | 20.57B | 19.57B | 18.65B |
| Stockholders Equity | 6.66B | 6.50B | 6.07B | 6.11B | 5.76B | 6.04B |
Cash Flow | ||||||
| Free Cash Flow | 2.08B | 2.05B | 2.11B | 1.50B | 1.59B | 2.30B |
| Operating Cash Flow | 2.74B | 2.65B | 2.72B | 2.15B | 2.26B | 2.94B |
| Investing Cash Flow | -2.24B | -2.31B | -1.44B | -1.60B | -2.01B | -2.10B |
| Financing Cash Flow | -34.00M | -150.00M | -878.00M | -382.00M | -329.00M | -1.24B |
IQVIA Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Neutral. The current price of 257.60 is below the 20-day moving average (MA) of 270.48, below the 50-day MA of 267.32, and above the 200-day MA of 211.33, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 40.36 is Neutral, neither overbought nor oversold. The STOCH value of 21.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IQV.
IQVIA Holdings Risk Analysis
IQVIA Holdings disclosed 51 risk factors in its most recent earnings report. IQVIA Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksIQVIA Holdings Peers Comparison
Overall Rating
MEDP84Outperform
DGX76Outperform
LH75Outperform
IQV74Outperform
ICLR71Outperform
CRL62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | $18.27B | 35.32 | 99.76% | ― | 20.35% | 25.24% | |
| 76Outperform | $28.20B | 25.20 | 15.21% | 1.32% | 9.13% | 17.93% | |
| 75Outperform | $29.90B | 30.09 | 11.54% | 0.78% | 6.02% | 19.63% | |
| 74Outperform | $42.45B | 31.11 | 21.82% | ― | 8.88% | 13.11% | |
| 71Outperform | $14.61B | 33.26 | 4.85% | ― | 0.67% | 43.70% | |
| 62Neutral | $15.92B | 326.42 | 1.32% | ― | -1.16% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IQV | IQVIA Holdings | 257.60 | 40.12 | 18.45% | |
| CRL | Charles River Laboratories Intl | 332.16 | 170.52 | 105.49% | |
| ICLR | Icon Plc | 195.02 | 36.21 | 22.80% | |
| LH | Labcorp Holdings Inc. | 368.24 | 110.30 | 42.76% | |
| DGX | Quest Diagnostics | 256.35 | 73.47 | 40.17% | |
| MEDP | Medpace Holdings Inc | 653.09 | 60.91 | 10.29% |
IQVIA Holdings Corporate Events
IQVIA Holdings Completes $2 Billion Senior Notes Issuance
NeutralOn September 23, 2026, IQVIA Inc., a subsidiary of IQVIA Holdings, completed a $2 billion issuance of 6.375% senior notes due March 15, 2034, structured as unsecured obligations with semi-annual interest payments starting March 15, 2027. The notes, i...
IQVIA Holdings Announces $2 Billion Senior Notes Offering
PositiveOn September 9, 2026, IQVIA Holdings Inc. announced that its wholly owned subsidiary IQVIA Inc. plans to raise $2 billion through a private offering of senior notes due 2034. The notes, bearing interest at 6.375% per annum, are being marketed to qual...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
